Loading...
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant...
Na minha lista:
| Udgivet i: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4913332/ https://ncbi.nlm.nih.gov/pubmed/27366220 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16638833 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|